A cisplatin-incorporated liposome that targets the epidermal growth factor receptor enhances radiotherapeutic efficacy without nephrotoxicity
JOOHEE JUNG, SEONG-YUN JEONG, SEOK SOON PARK, SEOL HWA SHIN, EUN JIN JU, JINHYANG CHOI, JAESOOK PARK, JAE HEE LEE, INKI KIM, YOUNG-AH SUH, JUNG JIN HWANG, SHUN'ICHI KURODA
(+3 others)
2014
International Journal of Oncology
radiotherapy (rt) is one of the major modalities for non-small cell lung cancer (NSCLC), but its efficacy is often compromised by cellular resistance caused by various mechanisms including the overexpression of epidermal growth factor receptor (egfr). although cis-diamminedichloroplatinum(Ⅱ) (cisplatin, cDDP) has been well characterized as an effective radiosensitizer, its clinical application is limited by its severe nephrotoxic effects. in our current study, we developed a cDDP-incorporated
more »
... posome (lP) conjugated with egfr antibodies (egfr:lP-cDDP) and evaluated its potential to radiosensitize egfr-overexpressing cells without exerting nephrotoxic effects. egfr:lP-cDDP showed higher cytotoxicity than non-targeting liposomal cDDP (lP-cDDP) in the cells expressing egfr in vitro. in an a549 cell-derived xenograft tumor mouse model, increased delays in tumor growth were observed in the mice treated with a combination of egfr:lP-cDDP and radiation. notably, the egfr:lP-cDDP-treated animals showed no differences in body weight loss, survival rates of nephrotoxicity compared with untreated control mice. in contrast, the use of cDDP caused lower body weights and poorer survival outcomes accompanied by a significant level of nephrotoxicity [e.g., decreased kidney weight, increased blood urea nitrogen (Bun) and creatinine, and pathological change]. these findings suggest the feasibility of using egfr:lP-cDDP to radiosensitize cells in a targeted manner without inducing nephrotoxic effects. this compound may therefore have clinical potential as part of a tailored chemoradiotherapy strategy. institute for innovative cancer research, asan medical center, university of ulsan college of medicine, Seoul 138-736; 2 college of Pharmacy and 3 innovative Drug center, Duksung women's university, Seoul 132-714; 4 asan institute for life Sciences, asan medical center, university of ulsan college of medicine, Seoul 138-736, republic of korea; 5 Department of Bioengineering Sciences, graduate School of Bioagricultural Sciences nagoya university, aichi 464-8601, japan; 6 Department of internal medicine, university of ulsan college of medicine; 7 Department of radiation oncology, asan medical center, university of ulsan college of medicine; 8 center for Development and commercialization of anti-cancer therapeutics, asan medical center, Seoul 138-736, republic of korea Si yeol Song, Department of radiation oncology, asan medical center, university of ulsan college of medicine, 88 olympic-ro 43-gil, Songpa-gu, Seoul 138-736, republic of korea
doi:10.3892/ijo.2014.2806
pmid:25544240
fatcat:4lzucyfgbng3ppibe5xkjrkzuy